UK regulatory landscape
Semaglutide (Wegovy) in the UK: dispensing landscape
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-05-20
Semaglutide, marketed in the UK as Wegovy, is a prescription-only medicine (POM) regulated by the MHRA. We publish this page as a regulatory and dispensing-landscape reference, not a recommendation. Your UK-licensed prescriber decides whether semaglutide is appropriate for you, based on the SmPC, the PIL, and your individual clinical picture. The UK landscape shifted materially in April 2026 when the cardiovascular outcome indication was approved, broadening the eligible population in NHS England commissioning. This page sets out the framework: MHRA authorisation, the NHS pathway, and the legitimate private routes.
NHS pathway
NHS England access
The April 2026 cardiovascular outcome indication added a separate NHS access route for adults with established cardiovascular disease, distinct from the tirzepatide NICE TA1026 cohort pathway. NHS access is via specialist weight management services in line with local ICB commissioning.
Read the NHS access editorial →
Private route
CQC-registered clinics
Independent CQC-registered providers in the UK whose formulary includes semaglutide include Numan, Voy, Manual, and Juniper. These app-based programmes pair a prescriber consultation with ongoing clinical review. Whether semaglutide is appropriate is a decision for your prescriber.
UK regulated clinic directory →
Pharmacy route
GPhC-registered pharmacies
UK GPhC-registered pharmacies that dispense semaglutide following a prescriber consultation include Phlo, Pharmacy2U, SimplyMeds, Boots Online Doctor, and Asda Online Doctor. Dispensing requires a valid UK prescription issued by a registered prescriber.
UK regulated pharmacy directory →
Semaglutide and tirzepatide in the UK regulatory context
Semaglutide is a single-mechanism GLP-1 receptor agonist. Tirzepatide is a dual GIP and GLP-1 receptor agonist. Both hold MHRA marketing authorisations for weight management in defined populations as set out in their respective SmPCs. As of April 2026, semaglutide additionally holds a cardiovascular outcome indication in the UK; tirzepatide does not at the time of writing. Editorial commentary on the clinical comparison is published separately. This page does not recommend one molecule over the other for any individual.
Further editorial: tirzepatide vs semaglutide editorial.
Important: POM, your UK-licensed prescriber decides
Semaglutide (Wegovy) is a prescription-only medicine. PeptideClear is an editorial publication, not a pharmacy, not a clinic, and not a prescriber. We do not sell, dispense, or recommend semaglutide for any individual. We publish this page as a UK regulatory and dispensing-landscape reference. Your UK-licensed prescriber, working from the MHRA-approved SmPC, the PIL, NHS England guidance, and your clinical picture, decides whether semaglutide is appropriate for you.